New monoclonal antibody vaccine slashes malaria risk in children
A recent study demonstrates that the monoclonal antibody-based vaccine L9LS is safe for children aged 6 to 10 and significantly reduces the risk of malaria infection and clinical symptoms by 70% and 77%, respectively.
Kateryna Kon Subcutaneous Administration International Council For Harmonisation Good Clinical Practises Drug Administration National Institute Of Allergy World Health Organization
Source: news-medical.net